Lantern Pharma Inc. 2022 Form 10-K Summary
Business context and reporting period
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on using artificial intelligence, machine learning, genomic data and its RADR® platform to develop precision oncology therapies. This filing covers the fiscal year ended December 31, 2022; it is an annual report, not a quarterly filing.
- Pipeline: LP-300 in a Phase II trial; LP-100 in clinical development planning; LP-184 and LP-284 in preclinical development; and an antibody-drug conjugate research program.
- RADR® reportedly contains more than 25 billion oncology-focused data points and is used for biomarker identification, patient stratification, drug rescue and combination-therapy analysis.
- No drug candidate had received regulatory or marketing approval, and the company had not generated operating revenue other than historical research-grant revenue.
- As of March 1, 2023, the company reported more than 80 active patents and patent applications across more than 14 patent families.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.603 million | $7.571 million |
| General and administrative expense | $5.830 million | $5.021 million |
| Total operating expenses | $14.433 million | $12.592 million |
| Loss from operations | $(14.433) million | $(12.592) million |
| Net loss | $(14.260) million | $(12.363) million |
| Basic and diluted loss per share | $(1.31) | $(1.13) |
| Net cash used in operating activities | $(12.767) million | $(10.592) million |
| Cash and cash equivalents | $37.202 million | $51.524 million |
| Marketable securities | $17.994 million | $19.201 million |
| Working capital | $55.924 million | Not clearly provided in the filing text |
| Long-term debt | None | None |
Combined cash, cash equivalents and marketable securities were approximately $55.2 million at December 31, 2022. Total assets were $58.836 million, total liabilities were $2.798 million and stockholders’ equity was $56.038 million. The company stated that existing cash and cash equivalents were expected to fund operating expenses and capital expenditures for at least 12 months from the March 20, 2023 filing date, but it also expects to require substantial additional funding.
Marketable securities included government and agency securities, corporate bonds and mutual funds. The company reported approximately $968,000 of unrealized losses on these investments at year-end, primarily attributed to market conditions, and no credit-loss impairment charge.
Material changes versus the prior comparable period
- Net loss increased approximately 15% to $14.260 million from $12.363 million, while operating expenses increased approximately 15% to $14.433 million.
- Research and development expense increased approximately 14% to $8.603 million, driven primarily by higher research studies, consulting and R&D payroll costs.
- General and administrative expense increased approximately 16% to $5.830 million, primarily due to higher payroll, professional fees, legal and patent costs, travel, office expenses and rent.
- Operating cash use increased approximately 21% to $12.767 million.
- Cash and cash equivalents declined approximately $14.3 million, partly reflecting operating losses and $2.482 million of share repurchases. The $7 million repurchase authorization terminated on July 31, 2022.
- Financing cash flow changed from a $63.416 million inflow in 2021, primarily from the January 2021 equity offering, to a $2.182 million outflow in 2022.
- LP-300 R&D spending increased to approximately $2.870 million from $2.352 million. LP-284 spending was separately reported at approximately $904,000 in 2022.
- LP-184 R&D expense was approximately $3.104 million in 2022, after a $935,000 payment from a service provider offset related costs.
- The company released approximately $459,000 from escrow to Allarity Therapeutics for LP-100 drug-stock recertification, compared with the $1 million upfront payment expensed in 2021 for reacquiring LP-100 rights.
- Shares outstanding declined to 10.857 million at December 31, 2022 from 11.089 million, primarily due to repurchases, partially offset by warrant exercises.
Guidance, outlook, commentary, risks and unusual items
- Management expects operating losses and expenses to increase as it advances LP-300, prepares LP-184 and LP-284 for clinical trials, develops LP-100 and expands RADR®.
- The HARMONIC Phase II LP-300 trial was planned for approximately 90 never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor therapy. Five sites had been activated, with first patient enrollment anticipated in the second quarter of 2023.
- Management targeted Phase I trial launches for LP-184 and LP-284 in mid-2023, subject to regulatory clearance and completion of enabling work.
- The company formed Starlight Therapeutics in January 2023 to develop LP-184 in central nervous system and brain-cancer indications, using the name STAR-001 for those programs.
- Management planned to increase RADR® data points from more than 25 billion to approximately 50 billion by the end of 2023.
- The company expects to rely heavily on additional equity, debt, grants, licensing transactions or collaborations. It had no committed external funding source and stated that failure to raise capital could delay, reduce or eliminate development programs.
- All drug candidates remain subject to significant clinical, regulatory, manufacturing, intellectual-property and commercialization risks. LP-300 and LP-100 had previously failed pivotal or required clinical endpoints in broader populations; the company’s strategy depends on demonstrating benefit in biomarker-selected subgroups.
- The company relies on third-party contract research organizations and manufacturers, has no internal manufacturing facilities and lacks redundant supply arrangements.
- Potentially material contractual obligations include milestone payments, royalties and sublicense-sharing arrangements under the AF Chemicals, BioNumerik and Allarity agreements.
- Cash balances substantially exceeded FDIC insurance limits. The company also reported interest-rate, investment valuation, foreign-currency, cybersecurity, key-person and thinly traded-stock risks.
- No material pending or threatened litigation was reported. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor was not required to provide an internal-control attestation under the emerging-growth-company exemption.
Most important facts for investors to verify
- Whether cash and marketable securities, after ongoing clinical and preclinical spending, can support operations beyond the company’s stated 12-month runway.
- Actual enrollment, safety findings, biomarker strategy and efficacy results from the HARMONIC Phase II LP-300 trial.
- Regulatory status and timing of the planned LP-184 and LP-284 Phase I programs.
- Whether RADR®-based biomarker predictions translate into prospective clinical benefit rather than retrospective or preclinical results.
- Future financing needs, potential equity dilution and the terms of any licensing or collaboration transactions.
- Royalty, milestone, sublicense and development-diligence obligations under the company’s in-licensed and acquired rights.
- Manufacturing readiness, supply-chain reliability and third-party contractor performance for clinical materials.
- Patent expiration dates, pending application outcomes and the absence of issued patent protection specifically covering the RADR® platform.